Key Takeaways
- • William Blair has initiated biotech research coverage through veteran analyst Alethia Young, who initiated coverage of 13 biotechnology companies, per a Business Wire release dated October 21, 2026.
- • Young joined William Blair in May 2026 with 25 years of biotechnology and healthcare experience, most recently serving as chief financial officer of Bicycle Therapeutics.
- • Initial coverage spans 13 companies: Ascentage Pharma Group (AAPG), Cytokinetics (CYTK), Edgewise Therapeutics (EWTX), Faeth Therapeutics (FTH), IDEAYA Biosciences (IDYA), Immunome (IMNM), Kardigan (KARD), Palvella Therapeutics (PVLA), Arcus Biosciences (RCUS), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Tango Therapeutics (TNGX), and Wave Life Sciences (WVE).
- • Research themes include precision cardiovascular therapies, emerging commercial-stage biotechnology companies, and innovation targeting RAS-driven cancers.
Summary
William Blair announced that Alethia Young has initiated coverage of 13 biotechnology companies, according to a Business Wire release from Chicago. The launch marks the next step in the firm's continued expansion of its biotech research offering, which the company describes as part of a broader investment in its equities platform.
Young joined William Blair in May 2026. She brings 25 years of experience across biotechnology and healthcare, with roles on Wall Street and within the industry. Most recently she served as chief financial officer of Bicycle Therapeutics.
Her initial coverage universe includes Ascentage Pharma Group, Cytokinetics, Edgewise Therapeutics, Faeth Therapeutics, IDEAYA Biosciences, Immunome, Kardigan, Palvella Therapeutics, Arcus Biosciences, Revolution Medicines, Rhythm Pharmaceuticals, Tango Therapeutics, and Wave Life Sciences. Her inaugural research centers on precision cardiovascular therapies, emerging commercial-stage biotechnology companies, and innovation targeting RAS-driven cancers.
In comments included in the release, Young said she looks at the science and commercial opportunity alongside management teams, their strategy, and how those decisions shape capital allocation and long-term value. John Kreger, director of equity research at William Blair, said the launch represents an important milestone in the expansion of the firm's biotech research and gives clients a broader perspective on a complex and rapidly evolving sector.
Young joined William Blair in May 2026. She brings 25 years of experience across biotechnology and healthcare, with roles on Wall Street and within the industry. Most recently she served as chief financial officer of Bicycle Therapeutics.
Her initial coverage universe includes Ascentage Pharma Group, Cytokinetics, Edgewise Therapeutics, Faeth Therapeutics, IDEAYA Biosciences, Immunome, Kardigan, Palvella Therapeutics, Arcus Biosciences, Revolution Medicines, Rhythm Pharmaceuticals, Tango Therapeutics, and Wave Life Sciences. Her inaugural research centers on precision cardiovascular therapies, emerging commercial-stage biotechnology companies, and innovation targeting RAS-driven cancers.
In comments included in the release, Young said she looks at the science and commercial opportunity alongside management teams, their strategy, and how those decisions shape capital allocation and long-term value. John Kreger, director of equity research at William Blair, said the launch represents an important milestone in the expansion of the firm's biotech research and gives clients a broader perspective on a complex and rapidly evolving sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.